RxDoctor Payments Data

Lacona Blunt, APRN

Psychiatric/Mental Health · Corinth, MSNPI 1770173049

Payments from drug & device makers

$3,945in general payments, 2019–2025

Across 143 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$685
  • AbbVie$416
  • Alkermes, Inc.$360
  • Novo Nordisk$332
  • Otsuka America Pharmaceutical, Inc.$296
  • Axsome Therapeutics, Inc.$279
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$3,77796%
  • Education$1674%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,945 in reported general payments places this provider in the 85th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$5,590
Medicare patients
33
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate103$323,732
IngrezzaValbenazine Tosylate12$88,459
Abilify MaintenaAripiprazole16$50,705
VraylarCariprazine Hcl22$47,816
Lurasidone Hcl24$4,459
Haloperidol Decanoate30$1,905
Paliperidone ErPaliperidone11$1,901
Atomoxetine Hcl12$1,874
LoxapineLoxapine Succinate24$1,784
Buspirone Hcl198$1,620
Fluphenazine Decanoate17$1,517
Olanzapine84$1,025
Desvenlafaxine Succinate ErDesvenlafaxine Succinate32$995
Divalproex Sodium ErDivalproex Sodium45$983
Benztropine Mesylate72$908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$272$323,732103 claims
Neurocrine Biosciences, Inc.Ingrezza$161$88,45912 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$296$50,70516 claims
AbbVieVraylar$416$47,81622 claims
Teva Pharmaceuticals USA, Inc.Loxapine$216$1,78424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Corinth

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →